| Strength | 2.5 mg |
| Packaging Size | 0.5 ml |
| Brand | Mounjaro |
| Manufacturer | Lilly |
| Prescription | No |
| Packaging Type | Pre-filled pen |
Minimum order quantity: 1 Vial
Mounjaro (tirzepatide) is an innovative, once-weekly injectable medication used to improve blood sugar control in adults with type 2 diabetes. It belongs to a new class of medications known as dual GIP and GLP-1 receptor agonists. By activating both receptors, tirzepatide mimics the body’s natural incretin hormones to enhance insulin secretion, suppress glucagon, and slow gastric emptying—helping to regulate blood glucose more effectively.
The 2.5 mg/0.5 mL dose of Mounjaro is typically used as the starting dose in a treatment plan, allowing the body to gradually adjust to the medication. It is administered once weekly via subcutaneous injection in the abdomen, thigh, or upper arm using a prefilled, single-dose pen. After four weeks, healthcare providers may increase the dose depending on the patient’s response and tolerance.
In addition to its primary role in lowering blood glucose, Mounjaro has been associated with weight loss in clinical trials, making it a valuable option for patients who are overweight or obese. However, it is not approved for use in patients with type 1 diabetes or for weight management alone.
Common side effects include nausea, vomiting, diarrhea, and reduced appetite, particularly during the initial weeks of therapy. These effects often improve as the body adapts. Rare but serious risks include pancreatitis, kidney impairment, and hypersensitivity reactions.
Mounjaro 2.5 mg should be stored in a refrigerator (2°C to 8°C) and protected from light. Do not freeze. Before administration, the pen should be brought to room temperature.
With its unique dual-incretin action, Mounjaro represents a significant advancement in the treatment of type 2 diabetes, offering patients a powerful, convenient, and effective way to manage their condition starting with the 2.5 mg dose.